New antibody shot against tick virus heads to first human tests
NCT ID NCT07377253
First seen Jan 30, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This early-stage study tests a new antibody drug called TBE025 in 18 healthy adults aged 18 to 55. The goal is to see if it is safe and how the body processes it when given through a vein. Participants get a single dose and are closely monitored for side effects. This research helps find the right dose for future studies, but does not yet treat or cure tick-borne encephalitis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THE TICK-BORNE ENCEPHALITIS VIRUS (TBEV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Universitaire Hospitalier Vaudois (CHUV)
Lausanne, Canton of Vaud, 1011, Switzerland
Conditions
Explore the condition pages connected to this study.